Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(16):2299-306.
doi: 10.2217/fon.15.162.

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

Srinath Sundararajan  1 , Nicholas J Vogelzang  2
Affiliations

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

Srinath Sundararajan et al. Future Oncol. 2015.

Abstract

Oncologic therapeutics has evolved enormously as we entered the 21st century. Unfortunately, the treatment of advanced urothelial cancer has remained unchanged over the last two decades despite a better understanding of the genetic alterations in bladder cancer. Pathways such as the PI3K/AKT3/mTOR and FGFR have been implicated in urothelial bladder cancer. However, targeted therapies have not shown proven benefit yet and are still considered investigational. Recently, researchers have been successful in manipulating the systemic immune response to mount antitumor effects in melanoma, lung cancer and lymphoma. Historically, intravesical Bacillus Calmette-Guérin immunotherapy has been highly active in nonmuscle invasive bladder cancer. Early data suggest that immune checkpoint inhibitors will soon prove to be another cornerstone in the treatment armamentarium of advanced bladder cancer.

Keywords: PD-1; PD-L1; bladder cancer; immunotherapy.

PubMed Disclaimer

MeSH terms